DaVita Inc. (DVA)
| Market Cap | 12.58B |
| Revenue (ttm) | 11.53B |
| Net Income (ttm) | 771.45M |
| Shares Out | 109.01M |
| EPS (ttm) | 6.47 |
| PE Ratio | 18.40 |
| Forward PE | 14.41 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $119.01 |
| Previous Close | $118.84 |
| Change ($) | 0.17 |
| Change (%) | 0.14% |
| Day's Open | 119.44 |
| Day's Range | 118.46 - 119.96 |
| Day's Volume | 469,957 |
| 52-Week Range | 80.85 - 129.59 |
Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.
DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DENVER, July 21, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 3, 2021, at 5:00 p.m. ...
These stocks check all the right boxes for the Oracle of Omaha.
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
In September 2011, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) announced a new investment manager would join the business to work alongside the Orac...
DVA vs. AMED: Which Stock Is the Better Value Option?
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Healthcare stocks with long-term growth visibility can be important additions to investment portfolio when inflation runs high.
Investors continue to be optimistic about DaVita (DVA) on its slew of tie-ups and strength in its kidney care business.
According to the All-in-One Screener, a Premium feature of GuruFocus, four stocks in Berkshire Hathaway Inc.'s ( BRK.A , Financial)( BRK.B , Financial) equity portfolio that have high profitability and ...
DaVita (DVA) and NKF collaborate to help kidney patients seeking a living donor, thereby improving health equity in kidney transplant process.
NEW YORK, June 10, 2021 /PRNewswire/ -- DaVita Kidney Care and the National Kidney Foundation (NKF) today announced their collaboration in launching an innovative, yearlong pilot aimed at improving heal...
DVA vs. AMED: Which Stock Is the Better Value Option?
DENVER, June 2, 2021 /PRNewswire/ -- DaVita Kidney Care , a leading provider of home dialysis, launched virtual support groups through DaVita Care Connect®, a mobile health platform designed for home d...
3 Stocks to Bank on Rebounding Outpatient Home Health Industry
DVA vs. AMED: Which Stock Is the Better Value Option?
DENVER, May 13, 2021 /PRNewswire/ -- DaVita Kidney Care today announced that 60 of its nephrology nurses were honored with The DAISY Award for Extraordinary Nurses® during National Nurses Week. The awa...
Investor confidence is high on the DaVita (DVA) stock, courtesy of its solid prospects.
DENVER, May 10, 2021 /PRNewswire/ -- DaVita Kidney Care today announced the expansion of its home kidney care program to include the HomeChoice Claria Automated Peritoneal Dialysis (APD) system enable...
Herbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present.
DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 16.11% and -0.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of DaVita (NYSE:DVA) moved lower in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 14.21% year over year to $2.09, which beat the estimat...
DENVER, April 29, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2021. For the quarter, diluted earnings per share from continuing...
DENVER, April 27, 2021 /PRNewswire/ -- DaVita Inc. today announced its 2025 Environmental, Social and Governance (ESG) goals and released its new ESG reports, bolstering its commitment to corporate citi...
Solid performance by net dialysis and the related lab patient service segment are likely to have aided DaVita's (DVA) top line in the first quarter.
DENVER, April 22, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, April 29, 2021, at 5:00 p.m....
EAGAN, Minn., April 12, 2021 /PRNewswire/ -- Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced the launch of an innovative new program with VillageHealth − a DaVita integrated kidney ...
The following health care companies have grown their earnings per share over a five-year period. According to the GuruFocus discounted cash flow calculator as of March 31, all of them also trade with a ...
DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.
DENVER, March 29, 2021 /PRNewswire/ -- DaVita today published its inaugural Diversity & Belonging (D&B) report, which discloses its diversity metrics and roadmap for delivering its vision of cultivating...
Since dialysis is a stable business, Davita Inc (NYSE: DVA) remained resilient during the pandemic. However, now with acceleration in volumes is poised to begin, the company “is not as levered to the ex...
DENVER, March 25, 2021 /PRNewswire/ -- Today, the Biden administration announced a new partnership with dialysis providers to provide COVID-19 vaccinations to people receiving dialysis and health care p...
WALTHAM, Mass. and DENVER, March 23, 2021 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) and DaVita Kidney Care today announced an expanded agreement to provide home dialysis technology—i...
These stocks have not yet finished moving higher.
SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2021 / NephroSant, a kidney health spin out of UC San Francisco, today announced it has closed its oversubscribed Series A funding round of $16 million. DaVita...
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
DENVER, March 9, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced today that the company will participate in the 2021 Barclays Global Healthcare Conference. Joel Ackerman, DaVita's Chief Financial...
DENVER, Feb. 24, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the upsize and pricing of its previously announced private add-on offering of $750 million aggregate principal am...
DENVER, Feb. 24, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today that it has commenced a private add-on offering of $750 million aggregate principal amount of its 4.625% senior n...
Francis Chou (Trades, Portfolio), manager of Chou Associates Management, disclosed last week that his firm's top four sells during the fourth quarter of 2020 included the closure of its position in Spir...
Investors' confidence is high on the DaVita (DVA) stock, thanks to solid prospects.
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. ... [Read more...]
| Industry Medical Care Facilities | IPO Date Oct 31, 1995 |
| CEO Javier Rodriguez | Employees 67,000 |
| Stock Exchange NYSE | Ticker Symbol DVA |
Financial Performance
In 2020, DaVita's revenue was $11.55 billion, an increase of 1.42% compared to the previous year's $11.39 billion. Earnings were $773.64 million, a decrease of -4.60%.
Analyst Forecasts
According to 12 analysts, the average rating for DaVita stock is "Hold." The 12-month stock price forecast is 126.88, which is an increase of 6.61% from the latest price.